For US Healthcare Providers
To visit the global (BRAND) website, please choose from the options below:
Are you a healthcare provider?
The information provided on this website is intended expressly for healthcare providers in the United States.
Please select one of the following:
Sitemap
Looking for support?
Explore our library of downloadable resources to help support you on your journey with SUNHARBO.
IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS
Bleeding
- The rate of ISTH* major bleeding was similar between SUNHARBO and placebo groups (1.6 vs. 1.5 per 100 patient-years).
- The rate of ISTH major bleeding events within 90 days of treatment initiation was 4.5 vs. 3.1 per 100 patient-years in the SUNHARBO and placebo groups, respectively.
- In patients planned to receive DAPT, the rate of ISTH major bleeding events was 1.9 vs. 1.5 per 100 patient-years in the SUNHARBO and placebo groups, respectively.
- Among patients older than 75 years, the rate of ISTH major bleeding was 2.6 vs. 1.7 per 100 patient-years in the SUNHARBO and placebo groups, respectively.
- In the high-risk TIA subgroup, the rate of ISTH major bleeding was 2.9 vs. 1.0 per 100 patient-years in the SUNHARBO and placebo groups, respectively.
- The rate of gastrointestinal (GI) bleeding was higher in the SUNHARBO compared to placebo group (2.7 vs. 2.1 per 100 patient-years). The majority of GI bleeding events in the SUNHARBO group (74%) were clinically relevant non-major or minor bleeding, and the most frequent bleeding site was of rectal origin.
Diarrhea
- The most frequently reported (> 3%) adverse reaction in SUNHARBO-treated patients was diarrhea.
Hepatic Enzyme Increased
- SUNHARBO is associated with elevated hepatic enzymes. Substantial cholestatic liver injury or serious liver injury with jaundice were each reported in less than 0.02% of SUNHARBO-treated patients.
DRUG INTERACTIONS
- P-glycoprotein (P-gp) substrates - Concomitant use of SUNHARBO increased the exposure to digoxin. For digoxin and sensitive P-gp substrates where minimal concentration changes may increase the risk of adverse reactions, follow the recommendation in their approved product labeling.
- Combined P-gp and strong CYP3A4 inducers - Avoid concomitant use with combined P-gp and strong CYP3A4 inducers, which decreases SUNHARBO exposure and may lead to loss of efficacy.
USE IN SPECIFIC POPULATIONS
Pregnancy
- There are risks to the mother associated with untreated non-cardioembolic ischemic stroke or TIA and risk of bleeding in the mother and fetus or neonate associated with use of anticoagulants during pregnancy.
Lactation
- Breastfeeding is not recommended during treatment with SUNHARBO and for 5 days after the last dose due to the potential for serious adverse reactions in nursing infants, including bleeding.
Hepatic Impairment
- Patients with moderate to severe hepatic impairment (Child-Pugh B and C) may have intrinsic coagulation abnormalities and use of SUNHARBO in these patients is not recommended.
INDICATION
SUNHARBO® is indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIH Stroke Scale ≤ 15) or high-risk transient ischemic attack (TIA).
*International Society on Thrombosis and Haemostasis.
For additional important risk and use information, please see the full Prescribing Information.
Site Modified: 11/2026
BAYER, the Bayer Cross, and SUNHARBO are registered trademarks of Bayer. All other trademarks are property of their respective owners.
100 Bayer Boulevard, Whippany, NJ 07981 USA
©2026 Bayer. All rights reserved.
This site is intended for US healthcare providers only.
You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
For Bayer products, you can report these directly to Bayer by clicking here.